ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $17.17 million. The enterprise value is $25.23 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 41.54 million shares outstanding. The number of shares has increased by 68.68% in one year.
| Current Share Class | 41.54M |
| Shares Outstanding | 41.54M |
| Shares Change (YoY) | +68.68% |
| Shares Change (QoQ) | +17.90% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 6.57% |
| Float | 38.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.30 |
| Forward PS | 1.12 |
| PB Ratio | 1.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.69.
| Current Ratio | 0.96 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.92 |
Financial Efficiency
Return on equity (ROE) is -171.81% and return on invested capital (ROIC) is -43.42%.
| Return on Equity (ROE) | -171.81% |
| Return on Assets (ROA) | -28.85% |
| Return on Invested Capital (ROIC) | -43.42% |
| Return on Capital Employed (ROCE) | -190.84% |
| Revenue Per Employee | $58,208 |
| Profits Per Employee | -$431,792 |
| Employee Count | 96 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, ProPhase Labs has paid $12.83 million in taxes.
| Income Tax | 12.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.29% in the last 52 weeks. The beta is -0.76, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.76 |
| 52-Week Price Change | -84.29% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 53.24 |
| Average Volume (20 Days) | 2,548,149 |
Short Selling Information
The latest short interest is 951,470, so 2.29% of the outstanding shares have been sold short.
| Short Interest | 951,470 |
| Short Previous Month | 2.55M |
| Short % of Shares Out | 2.29% |
| Short % of Float | 2.49% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $5.59 million and -$41.45 million in losses. Loss per share was -$1.37.
| Revenue | 5.59M |
| Gross Profit | 1.33M |
| Operating Income | -31.33M |
| Pretax Income | -32.20M |
| Net Income | -41.45M |
| EBITDA | -25.45M |
| EBIT | -31.33M |
| Loss Per Share | -$1.37 |
Full Income StatementBalance Sheet
The company has $171,000 in cash and $7.87 million in debt, giving a net cash position of -$7.70 million or -$0.19 per share.
| Cash & Cash Equivalents | 171,000 |
| Total Debt | 7.87M |
| Net Cash | -7.70M |
| Net Cash Per Share | -$0.19 |
| Equity (Book Value) | 11.44M |
| Book Value Per Share | 0.28 |
| Working Capital | -1.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.18 million and capital expenditures -$39,000, giving a free cash flow of -$11.22 million.
| Operating Cash Flow | -11.18M |
| Capital Expenditures | -39,000 |
| Free Cash Flow | -11.22M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
| Gross Margin | 23.71% |
| Operating Margin | -560.61% |
| Pretax Margin | -623.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.68% |
| Shareholder Yield | -68.68% |
| Earnings Yield | -236.35% |
| FCF Yield | -63.99% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 23, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ProPhase Labs has an Altman Z-Score of -3.78 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.78 |
| Piotroski F-Score | 4 |
